At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 205 enrolled
Drug / intervention
fulvestrant +1 moredrug
Likely dose
fulvestrant 500 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Open-Label, Parallel-Group, Multicentre, Phase II Study to Compare the Efficacy and Tolerability of Fulvestrant (FASLODEX™) 500 mg With Anastrozole (ARIMIDEX™) 1 mg as First Line Hormonal Treatment for Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer
In Brief
A Phase 2 clinical trial evaluating fulvestrant and anastrozole for Metastatic Breast Cancer. Completed, enrolled 205 participants across 41 sites in 9 countries.
Detailed Summary
The purpose of this study is to compare the efficacy and tolerability of Faslodex (fulvestrant) with Arimidex (anastrozole) in postmenopausal women with hormone receptor positive advanced breast cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic Breast Cancer
CountriesBrazil, Bulgaria, Czechia, France, Italy, Poland, Spain, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 2006
Enrollment StartFeb 2006
Primary CompletionJan 2008
Study CompletionJan 2017
TodayJul 2026
First PostedJan 11, 2006
Enrollment StartFeb 6, 2006
Primary CompletionJan 10, 2008
Study CompletionJan 13, 2017
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 20.5 years ago
Interventions
fulvestrantdrug
500 mg intramuscular injection
anastrozoledrug
1 mg oral tablet